Drugs for Impotence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 238)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Nebivolol |
Approved, Investigational |
Phase 4 |
|
152520-56-4, 99200-09-6, 118457-14-0 |
71301 |
Synonyms:
1,1'-[Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)]-2,2'-iminodiethanol
1,1'-Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2,2'-iminodiethanol
a,Alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
alpha,Alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol
alpha,Alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
ALPHA,ALPHA'-(IMINODIMETHYLENE)BIS-(6-FLUORO-2-CHROMANMETHANOL)
Bystolic
Bystolic®|R-65824|Ro-67555
Hydrochloride, nebivolol
HYPOLOC
Lobivon
NARBIVOLOL
Nebicard-5
Nebilet
|
Nebilong
Nebipill
NEBIVOLOL
Nebivolol hydrochloride
NEBIVOLOLUM
nebivololum [latin]
Nodon
Nubeta
PI-21858
R-65824
RO-67555
Silostar
Α,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
|
|
2 |
|
Selegiline |
Approved, Investigational, Vet_approved |
Phase 4 |
|
14611-51-9, 14611-52-0 |
5195 26757 |
Synonyms:
(−)-selegiline
Apo-Selegiline
Bristol myers squibb brand OF selegiline
Bristol-myers squibb brand OF selegiline
Carbex
CENTRAPRYL 10
CENTRAPRYL 5
Deprenalin
Deprenil
Deprenyl
Eldepryl
Eldepryl®|L-deprenalin|Otrasel®|Selegene®|Zelapar®
Emsam
ENSAM
Gen-Selegiline
Humex
Hydrochloride, selegiline
Jumex
L-Deprenalin
L-Deprenyl
Novo-Selegiline
Nu-Selegiline
Sd Deprenyl
|
Selegeline Hcl
Selegilina
Selegilina [INN-Spanish]
SELEGILINE
SELEGILINE HCL
Selegiline hydrochloride
Selegiline hydrochloride, (R)-isomer
Selegiline hydrochloride, (R,S)-isomer
Selegiline hydrochloride, (S)-isomer
Selegiline valeant brand
Selegiline, (R)-isomer
Selegiline, (R,S)-isomer
Selegiline, (S)-isomer
Selegilinum
Selegilinum [INN-Latin]
Selegyline
STILLINE 10
STILLINE 5
Valeant brand OF selegiline
VIVAPRYL
Yumex
Zelapar
|
|
3 |
|
Valsartan |
Approved, Investigational |
Phase 4 |
|
137862-53-4 |
60846 |
Synonyms:
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
CGP-48933
CGP-48933|Diovan®|Prexxartan® (oral solution)
Diovan
EXFORGE
Kalpress
Miten
N-(p-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Nisis
|
N-Pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-Valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
PREXXARTAN
Provas
Tareg
VAL489
Vals
VALSARTAN
|
|
4 |
|
Nitric Oxide |
Approved |
Phase 4 |
|
10102-43-9 |
145068 |
Synonyms:
(.)NO
(NO)(.)
[NO]
EDRF
Endogenous nitrate vasodilator
Endothelium-derived nitric oxide
Endothelium-derived relaxing factor
HYDROXYAMINE
INOmax
INOmax®|nitric oxide|nitrogen monoxide
Mononitrogen monoxide
Monoxide, mononitrogen
Monoxide, nitrogen
Monoxido de nitrogeno
Monóxido de nitrógeno
Monoxyde d'azote
Nitrate vasodilator, endogenous
NITRIC OXIDE
Nitric oxide, endothelium derived
Nitric oxide, endothelium-derived
Nitrogen monooxide
|
Nitrogen monoxide
Nitrogen oxide
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl radical
Nitroxide radical
Nitroxyl
NO
NO(.)
OHM-11771
Oxide, nitric
Oxido de nitrogeno(II)
óxido de nitrógeno(II)
Oxido nitrico
óxido nítrico
Oxyde azotique
Oxyde nitrique
Stickstoff(II)-oxid
Stickstoffmonoxid
Vasodilator, endogenous nitrate
|
|
5 |
|
Tacrolimus |
Approved, Investigational |
Phase 4 |
|
104987-11-3 |
6473866 445643 |
Synonyms:
(-)-FK 506
Anhydrous tacrolimus
Anhydrous, tacrolimus
Cilag brand OF tacrolimus
FK5
FK506
FK-506
FK506|fujimycin|Prograf®|Protopic®
FR-900506
FUJIMYCIN
Fujisawa brand OF tacrolimus
Janssen brand OF tacrolimus
|
K506
LCP-Tacro
Prograf
Prograft
PROTOPIC
Tacarolimus
TACROLIMUS
Tacrolimus anhydrous
tacrolimus hydrate
TACROLIMUS MONOHYDRATE
Tacrolimus, anhydrous
|
|
6 |
|
Allantoin |
Approved |
Phase 4 |
|
97-59-6 |
204 |
Synonyms:
(2,5-Dioxo-4-imidazolidinyl)urea
(S)-Allantoin
2,5-Dioxo-4-imidazolidinyl-urea
4-Ureido-2,5-imidazolidinedione
5-Ureido-2,4-imidazolidindione
5-Ureidohydantoin
5-Ureido-hydantoin
5-Ureidohydrantoin
Alantan
Alantoína
ALLANTOIN
Allantoin campbell brand
Allantoin sween brand
Allantol
Alloxantin
AVC/Dienestrolcream
Campbell brand OF allantoin
|
Cordianine
D00121
Fancol toin
Glyoxyldiureid
Glyoxyldiureide
Glyoxylic diureide
Herpecin L
HerpecinL
Herpecin-L
N-(2,5-Dioxo-4-imidazolidinyl)urea
Psoralon
Reed and carnrick brand OF allantoin
Sebical
Septalan
Sween brand OF allantoin
Woun'dres
|
|
7 |
|
Curcumin |
Approved, Investigational |
Phase 4 |
|
458-37-7, 84765-67-3 |
969516 |
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
14a-Methyl-9,19-cyclo-5a,9b-cholestane-3b,6a-diol
C.I. 75300
C.I. natural yellow 3
CI natural yellow 3
CI-75300
Cucurmin
Curcuma
CURCUMIN
Curcumin I
Diferaloylmethane
Diferuloylmethane
e 100
E100
E-100
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
|
Hydrastis
INS NO. 100(I)
INS-100(I)
Kacha haldi
Merita earth
Natural yellow 3
NSC-32982
NSC-687842
Orange root
Safran d'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yellow, turmeric
Yo-kin
|
|
8 |
|
Zinc cation |
Approved, Experimental, Investigational |
Phase 4 |
|
7440-66-6, 23713-49-7 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
Mannosidase b, alpha
Neutral alpha mannosidase
|
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc ion(2+)
Zinc(2+)
Zinc(II)
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
zinc|zinc ion
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
9 |
|
Yohimbine |
Approved, Investigational, Vet_approved |
Phase 4 |
|
146-48-5 |
8969 |
Synonyms:
(+)-Yohimbine
(16a,17a)-17-Hydroxyyohimban-16-carboxylate methyl ester
(16a,17a)-17-Hydroxyyohimban-16-carboxylic acid methyl ester
(16alpha,17alpha)-17-Hydroxyyohimban-16-carboxylate methyl ester
(16alpha,17alpha)-17-Hydroxyyohimban-16-carboxylic acid methyl ester
(16Α,17α)-17-hydroxyyohimban-16-carboxylate methyl ester
(16Α,17α)-17-hydroxyyohimban-16-carboxylic acid methyl ester
17a-Hydroxyyohimban-16a-carboxylate methyl ester
17a-Hydroxyyohimban-16a-carboxylic acid methyl ester
17alpha-Hydroxyyohimban-16alpha-carboxylate methyl ester
17alpha-Hydroxyyohimban-16alpha-carboxylic acid methyl ester
17Α-hydroxyyohimban-16α-carboxylate methyl ester
17Α-hydroxyyohimban-16α-carboxylic acid methyl ester
ACTIBINE
Actibine®|corynine|quebrachin|yohimbin
Aphrodine
Aphrodine hydrochloride
Aphrodyne
Aventis brand OF yohimbine hydrochloride
Corynanthine
Corynanthine tartrate
Corynine
Glenwood brand OF yohimbine hydrochloride
Hydrochloride, aphrodine
|
Hydrochloride, yohimbine
Johimbin
Kramer brand OF yohimbine hydrochloride
Palisades brand OF yohimbine hydrochloride
Pluriviron
Quebrachin
Quebrachine
Rauhimbine
Rauwolscine
Solvay brand OF yohimbine hydrochloride
Star brand OF yohimbine hydrochloride
StegroPharm brand OF yohimbine hydrochloride
Tartrate, corynanthine
Yocon
Yohimbate methyl ester
Yohimbic acid methyl ester
Yohimbin
Yohimbin spiegel
YOHIMBINE
Yohimbine houdé
Yohimbine hydrochloride
Yohimbinum
Yohimex
|
|
10 |
|
Angiotensin II |
Approved, Investigational |
Phase 4 |
|
68521-88-0, 11128-99-7, 4474-91-3 |
172198 |
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
Angiotensin-(1-8) octapeptide
Angiotonin
|
Asp-arg-val-tyr-ile-his-pro-phe
Delivert
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-Α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
11 |
|
Hydrochlorothiazide |
Approved, Vet_approved |
Phase 4 |
|
58-93-5 |
3639 |
Synonyms:
3,4-Dihydrochlorothiazide
6-CHLORO-1,1-DIOXO-3,4-DIHYDRO-2H-1$L^{6},2,4-BENZOTHIADIAZINE-7-SULFONAMIDE
Acuretic
Aldactazide
Aldoril
APO-HYDRO
Apo-hydro®
Apresazide
Aquarills
Aquarius
Bremil
Caplaril
Capozide
Chlorosulthiadil
Chlorothiazide
Chlorsulfonamidodihydrobenzothiadiazine dioxide
Chlorzide
Cidrex
COTAREG
Dichlorosal
Dichlorotride
Dichlothiazide
Dichlotiazid
Dichlotride
Diclotride
Dicyclotride
Dihydrochlorothiazid
Dihydrochlorothiazide
Dihydrochlorothiazidum
Dihydrochlorurit
Dihydrochlorurite
Dihydroxychlorothiazidum
Direma
Disalunil
Diu-Melusin
Diuril
Drenol
Dyazide
ESI879
Esidrex
Esidrix
ESIDRIX (TN)
Esimil
Fluvin
HCT
HCTZ
HCZ
Hidril
Hidrochlortiazid
Hidroclorotiazida
Hidroronol
Hidrotiazida
Hydril
|
Hydro-aquil
Hydrochloro thiazide
Hydrochlorothiazid
HYDROCHLOROTHIAZIDE
Hydrochlorothiazide intensol
Hydrochlorothiazidum
Hydrochlorthiazide
Hydro-D
Hydrodiuretic
Hydrodiuril
Hydro-diuril
Hydropres
Hydrosaluric
Hydrothide
Hydrozide
Hypothiazid
Hypothiazide
Hyzaar
Idrotiazide
Inderide
Ivaugan
Jen-diril
Lopressor HCT
Lotensin HCT
Maschitt
Maxzide
Megadiuril
Microzide
Moduretic
Nefrix
Neo-codema
Neoflumen
Newtolide
NSC-53477
Oretic
Panurin
Prinzide
Ro-hydrazide
Sectrazide
Ser-ap-es
Servithiazid
SU-5879
Thiaretic
Thiuretic
Thlaretic
Timolide
Unipres
Urodiazin
Vaseretic
Vetidrex
Ziac
Zide
|
|
12 |
|
Bupivacaine |
Approved, Investigational |
Phase 4 |
|
2180-92-9, 38396-39-3 |
2474 |
Synonyms:
(+-)-Bupivacaine
(±)-bupivacaine
(RS)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
Abbott brand OF bupivacaine hydrochloride
ANEKAIN
Anhydrous, bupivacaine
Astra brand OF bupivacaine hydrochloride
AstraZeneca brand OF bupivacaine hydrochloride
Aventis brand OF bupivacaine hydrochloride
Bloqueina
Braun brand OF bupivacaine hydrochloride
Braun, bupivacaina
Bucaine
Bupivacain janapharm
Bupivacain RPR
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaina braun
BUPIVACAINE
Bupivacaine anhydrous
Bupivacaine carbonate
Bupivacaine HCL
Bupivacaine HCL kit
Bupivacaine hydrochloride
Bupivacaine monohydrochloride, monohydrate
Bupivacain-RPR
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
Buvacaina
|
Carbonate, bupivacaine
Carbostesin
CBupivacaine
Chirocaine
DepoBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
DL-Bupivacaine|Exparel®|Marcain®|Posimir®|Sensorcaine®|W-7|Xaracoll®
Dolanaest
DUR-843
Exparel
Hydrochloride, bupivacaine
Inibsa brand OF bupivacaine hydrochloride
Janapharm, bupivacain
Jenapharm brand OF bupivacaine hydrochloride
LAC-43
LIQ865
LIQ-865
Marcain
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
Pisa brand OF bupivacaine hydrochloride
Racemic bupivacaine
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
SKY-0402
Strathmann brand OF bupivacaine hydrochloride
Svedocain sin vasoconstr
Transdur-Bupivacaine
|
|
13 |
|
Ropivacaine |
Approved |
Phase 4 |
|
84057-95-4 |
71273 175805 |
Synonyms:
(-)-1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
(-)-1-Propyl-2',6'-pipecoloxylidide
(+-)-Ropivacaine
(S)-(-)-1-Propyl-2',6'-pipecoloxylidide
(S)-(−)-1-PROPYL-2',6'-PIPECOLOXYLIDIDE
(S)-ROPIVACAINE
1 Propyl 2',6' pipecoloxylidide
1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
1-Propyl-2',6'-pipecoloxylidide
1-propyl-2',6'-pipecoloxylidide|AL-381|LEA-103|Naropin®|ropivacaine hydrochloride
AL-381
DL-Ropivacaine
LEA 103
LEA-103
L-N-N-Propylpipecolate-2,6-xylidide
L-N-N-Propylpipecolic acid-2,6-xylidide
Naropeine
|
Naropin
N-N-Propylpipecolate-2,6-xylidide
N-N-Propylpipecolic acid-2,6-xylidide
Racemic ropivacaine
rac-Ropivacaine
Ropivacaina
Ropivacaina [INN-Spanish]
Ropivacaina [Spanish]
Ropivacaine
Ropivacaine [INN]
Ropivacaine hydrochloride
Ropivacaine monohydrochloride
Ropivacaine monohydrochloride, (S)-isomer
Ropivacainum
Ropivacainum [INN-Latin]
S-Ropivacaine
|
|
14 |
|
Testosterone |
Approved, Investigational |
Phase 4 |
|
58-22-0 |
5408 6013 |
Synonyms:
(+-)-8-ISO-TESTOSTERONE
(+-)-RETROTESTOSTERONE
(+)-TESTOSTERONE
(+-)-TESTOSTERONE
(17B)-17-HYDROXY-ANDROST-4-EN-3-ONE
(1S,2R,10R,11S,14S,15S)-14-HYDROXY-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
13-ISO-TESTOSTERONE
17 beta Hydroxy 4 androsten 3 one
17 beta Hydroxy 8 alpha 4 androsten 3 one
17A-HYDROXY-(13A)-ANDROST-4-EN-3-ONE
17A-HYDROXY-13A-ANDROST-4-EN-3-ONE
17A-HYDROXY-14B-ANDROST-4-EN-3-ONE
17A-HYDROXY-ANDROST-4-EN-3-ONE
17-beta-Hydroxy-4-androsten-3-one
17BETA-HYDROXY-4-ANDROSTEN-3-ONE
17-beta-Hydroxy-8 alpha-4-androsten-3-one
17B-HYDROXY-(10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(13A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(8A,10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(9B)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(9B,10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-13A-ANDROST-4-EN-3-ONE
17b-Hydroxy-4-androsten-3-one
17B-HYDROXY-8A-ANDROST-4-EN-3-ONE
17B-HYDROXY-ANDROST-4-EN-3-ON
17B-HYDROXYANDROST-4-EN-3-ONE
17B-HYDROXY-ANDROST-4-EN-3-ONE
17B-HYDROXYANDROST-4-ENE-3-ONE
17B-HYDROXY-D4-ANDROSTEN-3-ONE
17B-TESTOSTERONE
17-HYDROXY-10,13-DIMETHYL-1,2,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
17-HYDROXY-ANDROST-4-EN-3-ONE
17-HYDROXY-D4-ANDROSTEN-3-ONE
17Î’-hydroxy-4-androsten-3-one
4-ANDROSTEN-17BETA-OL-3-ONE
4-Androsten-17b-ol-3-one
4-ANDROSTEN-17Î’-OL-3-ONE
4-ANDROSTEN-3-ONE-17B-OL
8 Isotestosterone
8-Isotestosterone
8-ISO-TESTOSTERONE
9B,10A-TESTOSTERONE
9B-TESTOSTERONE
Andriol
Andro
Andro 100
Andro L.A. 200
ANDRODERM
Androderm®|Delatestryl®
ANDROGEL
ANDROGEL 1%
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
ANDROPATCH
Andropository 200
Androsorb
ANDROST-4-EN-17B-OL-3-ONE
ANDROST-4-ENE-17B-OL-3-ONE
Androtop
Andrusol
Andryl 200
AstraZeneca brand OF testosterone
Auxilium pharmaceuticals inc. brand OF testosterone
AXIRON
Bartor brand OF testosterone
Beta Testosterone
Bio-T-Gel
CDB 111C
CEPA brand OF testosterone
Cristerona T
Cristerone T
D4-ANDROSTEN-17B-OL-3-ONE
Dea No. 4000
Delatest
DELATESTRYL
Depotest
Depo-Testosterone
Depo-Testosterone Cypionate
Dr. kade brand OF testosterone
Epitestosteron
Everone 200
Faulding brand OF testosterone
Ferring brand OF testosterone
FORTESTA
Geno-cristaux gremy
GlaxoSmithKline brand OF testosterone
Hauck brand OF testosterone
Histerone
Homosteron
Homosterone
INTRINSA
Libigel
LUMITESTOSTERON
|
Malerone
Malestrone
Malogen in Oil
Malogen, Aquaspension Injection
MERTESTATE
Metandren
Methyltestosterone
NATESTO
Neo-Hombreol F
Neotestis
Neo-Testis
NSC-9700
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Ortho brand OF testosterone
Paladin brand OF testosterone
Pasadena brand OF testosterone
Perandren
Percutacrine androgenique
Primotest
Primoteston
RAC-17B-HYDROXY-(13A)ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-(9B,10A)ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-ANDROST-4-EN-3-ONE
Relibra
RETROTESTOSTERONE
Scheinpharm Testone-Cyp
Schering brand OF testosterone
SmithKline beecham brand OF testosterone
Solvay brand OF testosterone
Sterotate
STRIANT
STRIANT SR
Sustanon
Sustanone
Sustason 250
Synandrol F
T-Cypionate
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
TESTIM
TESTIM 1%
Testobase
TESTODERM
TESTODERM TTS
TESTOGEL
Testoject-50
Testolent
Testolin
TESTOPATCH
TESTOPEL
Testopel Pellets
Testopropon
TESTORAL
Testosteroid
TESTOSTERON
TESTOSTERONA
Testosterona [INN-Spanish]
TESTOSTERONE
TESTOSTÉRONE
TESTOSTERONE CIII
Testosterone Cypionate
Testosterone Enanthate
Testosterone Hydrate
Testosterone sulfate
TESTOSTERONUM
Testosteronum [INN-Latin]
Testostosterone
Testoviron
Testoviron schering
Testoviron T
Testred
Testred Cypionate 200
Testrin-P.A
Testro aq
TESTRONE
Testryl
TOSTRAN
Tostrelle
Tostrex
Trans-Testosterone
Ulmer brand OF testosterone
Unimed brand OF testosterone
Viatrel
Virilon
Virilon IM
Virormone
VIROSTERONE
VOGELXO
Watson brand OF testosterone
|
|
15 |
|
Methyltestosterone |
Approved |
Phase 4 |
|
58-18-4 |
6010 |
Synonyms:
17 alpha Methyltestosterone
17 beta Hydroxy 17 methyl 4 androsten 3 one
17 beta Methyltestosterone
17 beta-Hydroxy-17-methyl-4-androsten-3-one
17 beta-Methyltestosterone
17 Epimethyltestosterone
17(a)-Methyl-delta(4)-androsten-17(b)-ol-3-one
17(a)-Methyl-δ(4)-androsten-17(b)-ol-3-one
17(alpha)-Methyl-Delta(4)-androsten-17(beta)-ol-3-one
17(Α)-methyl-δ(4)-androsten-17(β)-ol-3-one
17alpha Methyl testosterone
17alpha Methyltestosterone
17alpha-Methyl-3-oxo-4-androsten-17beta-ol
17alpha-Methyl-Delta(4)-androsten-17beta-ol-3-one
17alpha-Methyl-delta-androsten-17beta-ol-3-one
17alpha-Methyltestosterone
17alpha-Methyl-testosterone
17-alpha-Methyltestosterone
17a-Methyl-3-oxo-4-androsten-17b-ol
17a-Methyl-delta(4)-androsten-17b-ol-3-one
17a-Methyltestosterone
17a-Methyl-δ(4)-androsten-17b-ol-3-one
17beta Hydroxy 17 methyl 4 androsten 3 one
17beta Methyltestosterone
17beta-Hydroxy-17-methyl-4-androsten-3-one
17beta-Hydroxy-17-methylandrost-4-en-3-one
17-beta-Hydroxy-17-methylandrost-4-en-3-one
17beta-Methyltestosterone
17b-Hydroxy-17-methylandrost-4-en-3-one
17-b-Hydroxy-17-methylandrost-4-en-3-one
17-Epimethyltestosterone
17-Methyltestosterone
17Α-methyl-3-oxo-4-androsten-17β-ol
17Α-methyltestosterone
17Α-methyl-δ(4)-androsten-17β-ol-3-one
17Α-METHYL-Δ4-ANDROSTEN-17Β-OL-3-ONE
17Î’-hydroxy-17-methylandrost-4-en-3-one
17-Î’-hydroxy-17-methylandrost-4-en-3-one
4-Androstene-17alpha-methyl-17beta-ol-3-one
4-Androstene-17a-methyl-17b-ol-3-one
|
4-Androstene-17α-methyl-17β-ol-3-one
Android
Android (methyltestoterone)
Android 10
Android 25
Android 5
Android-10
Android-25
Android-5
CDB-110
Global pharmaceutical brand OF methyltestosterone
ICN brand 1 OF methyltestosterone
ICN brand 2 OF methyltestosterone
L 589.372
L-589.372
L-589372
Mesteron
Mesterone
Metandren
Methitest
Methyltestosterone
METHYLTESTOSTERONE CIII
Methyltestosteronum
Metiltestosterona
NSC-139965
NSC-9701
Oreton
ORETON METHYL
PERANDREN
PLEX HORMONE
POTENSAN FTE
RU 24400
RU-24400
Schering brand OF methyltestosterone
Star brand OF methyltestosterone
Testoviron
TESTOVIS
Testred
U-2842
Virilon
|
|
16 |
|
Testosterone undecanoate |
Approved, Investigational |
Phase 4 |
|
5949-44-0 |
21873174 65157 |
Synonyms:
2,15-Dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadec-6-en-14-yl undecanoic acid
ANDRIOL
AVEED
JATENZO
MK-3033
NEBIDO
ORG-538
RESTANDOL
|
RESTANDOL TESTOCAP
Testosterone undecanoate
Testosterone undecanoic acid
Testosterone undeconate
Testosterone undecylate
TSX-011
UNDESTOR
|
|
17 |
|
Testosterone enanthate |
Approved |
Phase 4 |
|
315-37-7 |
9416 |
Synonyms:
17-((1-Oxoheptyl)oxy)androst-4-en-3-one
17beta-Enanthoxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-en-3-one enanthate
17beta-Hydroxyandrost-4-en-3-one heptanoate
17beta-Hydroxyandrost-4-en-3-one heptanoic acid
17b-Hydroxyandrost-4-en-3-one heptanoate
17b-Hydroxyandrost-4-en-3-one heptanoic acid
17-Hydroxyandrost-4-en-3-one, 17-heptanoate
17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid
17Î’-hydroxyandrost-4-en-3-one heptanoate
17Î’-hydroxyandrost-4-en-3-one heptanoic acid
4-Androsten-17beta-ol-3-one 17-enanthate
4-Androsten-3-one 17beta-enanthate
Androgyn l.a.
Andropository
Androtardyl
Atlatest
BTG Brand OF testosterone enanthate
DEA no. 4000
Delatest
Delatestryl
DePatestrye
depo-testro Med
Ditate
Durathate
eifelfango Brand OF testosterone enanthate
Everone
Exten test
Jenapharm brand OF testosterone enanthate
Malogen l.a.
Malogen l.a.200
NSC-17591
Orquisteron-e
Pasadena brand OF testosterone enanthate
Primoteston depot
|
Primotestone
reposo TMD
Roberts brand OF testosterone enanthate
Rotexmedica brand OF testosterone enanthate
Rugby brand OF testosterone enanthate
Schering brand OF testosterone enanthate
Testanthate
Testate
Testenate
Testinon
Testoenant
Testonenant
Testosteron depot-rotexmedica
Testosteron-depot eifelfango
Testosteron-depot jenapharm
Testosterone 17beta-heptanoate
Testosterone 17beta-heptanoic acid
Testosterone 17-enanthate
Testosterone 17-enanthic acid
Testosterone enantate
Testosterone enanthate
TESTOSTERONE ENANTHATE CIII
Testosterone enanthic acid
Testosterone heptanoate
Testosterone heptanoic acid
Testosterone heptoate
Testosterone heptoic acid
Testosterone heptylate
Testosterone oenanthate
Testostroval
Testrin p.a.
Theramed brand OF testosterone enanthate
Theramex
XYOSTED (AUTOINJECTOR)
|
|
18 |
|
Arginine |
Approved, Investigational, Nutraceutical |
Phase 4 |
|
74-79-3 |
6322 |
Synonyms:
(2S)-2-Amino-5-(carbamimidamido)pentanoate
(2S)-2-Amino-5-(carbamimidamido)pentanoic acid
(2S)-2-AMINO-5-(DIAMINOMETHYLIDENEAMINO)PENTANOIC ACID
(2S)-2-AMINO-5-[(DIAMINOMETHYLIDENE)AMINO]PENTANOIC ACID
(2S)-2-Amino-5-guanidinopentanoate
(2S)-2-Amino-5-guanidinopentanoic acid
(2S)-2-AMINO-5-GUANIDINO-PENTANOIC ACID
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid
(S)-2-Amino-5-guanidinopentanoate
(S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinovalerate
(S)-2-Amino-5-guanidinovaleric acid
2-Amino-5-guanidinovalerate
2-Amino-5-guanidinovaleric acid
5-[(Aminoiminomethyl)amino]-L-norvaline
Arg
Arginina
Arginine
|
Arginine hydrochloride
Arginine, L isomer
Arginine, L-isomer
DL Arginine acetate, monohydrate
DL-Arginine acetate, monohydrate
Hydrochloride, arginine
L Arginine
L-(+)-Arginine
L-a-Amino-D-guanidinovalerate
L-a-Amino-D-guanidinovaleric acid
L-alpha-Amino-delta-guanidinovalerate
L-alpha-Amino-delta-guanidinovaleric acid
L-Arg
L-Arginin
L-ARGININE
L-Isomer arginine
Monohydrate DL-arginine acetate
N5-(Aminoiminomethyl)-L-ornithine
NSC-206269
R
|
|
19 |
|
N,N-dimethylarginine |
Experimental |
Phase 4 |
|
30315-93-6 |
123831 |
Synonyms:
2-Amino-5-(amino-dimethylamino-methylidene)amino-pentanoate
2-Amino-5-(amino-dimethylamino-methylidene)amino-pentanoic acid
ADMA
Asymmetric dimethylarginine
Dimethyl-L-arginine
Guanidino-N,N-dimethylarginine
L-NG,NG-dimethylarginine
N(5)-((Dimethylamino)iminomethyl)-L-ornithine
N(g),N(g)-Dimethylarginine
|
N(g)-Dimethylarginine
N(g1),N(g1)-Dimethylarginine
N(Omega),N(omega)-dimethyl-L-arginine
N,N-Dimethylarginine
NG,NG-Dimethylarginine
NG,NG-Dimethyl-L-arginine
NG-Dimethylarginine
Nomega,nomega'-dimethyl-L-arginine
Nomega,nomega-dimethyl-L-arginine
|
|
20 |
|
Protective Agents |
|
Phase 4 |
|
|
|
21 |
|
Neuroprotective Agents |
|
Phase 4 |
|
|
|
22 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
23 |
|
Monoamine Oxidase Inhibitors |
|
Phase 4 |
|
|
|
24 |
|
Vardenafil Dihydrochloride |
|
Phase 4 |
|
|
|
25 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
26 |
|
Angiotensin Receptor Antagonists |
|
Phase 4 |
|
|
|
27 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
28 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
29 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
30 |
|
Adrenergic alpha-Antagonists |
|
Phase 4 |
|
|
|
31 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
32 |
|
Anticoagulants |
|
Phase 4 |
|
|
|
33 |
|
Chelating Agents |
|
Phase 4 |
|
|
|
34 |
|
Calcineurin Inhibitors |
|
Phase 4 |
|
|
|
35 |
|
Insulin, Globin Zinc |
|
Phase 4 |
|
|
|
36 |
|
Insulin |
|
Phase 4 |
|
|
|
Synonyms:
AFREZZA
EXUBERA
HUMULIN
HUMULIN BR
HUMULIN R
HUMULIN R KWIKPEN
HUMULIN R PEN
INS HUMULIN R
INSULIN
INSULIN (HUMAN)
INSULIN BOVINE
INSULIN BOVINE INSULIN
|
INSULIN HUMAN
INSULIN HUMAN (BIOSYNTHESIS)
INSULIN HUMAN (SYNTHESIS)
INSULIN RECOMBINANT HUMAN
INSULIN RECOMBINANT PURIFIED HUMAN
INSUMAN INFUSAT
MYXREDLIN
NOVOLIN
NOVOLIN R
VELOSULIN
VELOSULIN BR
VELOSULIN BR HUMAN
|
|
37 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
38 |
|
Yohimbe |
|
Phase 4 |
|
|
|
39 |
|
Mydriatics |
|
Phase 4 |
|
|
|
40 |
|
Angiotensinogen |
|
Phase 4 |
|
|
16133225 |
Synonyms:
Hypertensinogen
Proangiotensin
Renin substrate
Renin substrate tetradecapeptide
|
Renin-substrate
Serpin a8
SERPINA8
Tetradecapeptide, renin substrate
|
|
41 |
|
Angiotensin II Type 1 Receptor Blockers |
|
Phase 4 |
|
|
|
42 |
|
Giapreza |
|
Phase 4 |
|
|
|
43 |
|
Anesthetics |
|
Phase 4 |
|
|
|
44 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
45 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 4 |
|
|
|
46 |
|
Anabolic Agents |
|
Phase 4 |
|
|
|
47 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
48 |
|
Hormones |
|
Phase 4 |
|
|
|
49 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
50 |
|
Androgens |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 534)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Observational Study to Evaluate the Effect of Tadalafil 5mg Once Daily on Erectile Dysfunction and QOL in Andropause Patients With Erectile Dysfunction |
Unknown status |
NCT02943356 |
Phase 4 |
Tadalafil |
2 |
Nebivolol Effects on Endothelial Function and Erectile Function in Non-smoking Pre-hypertensive and Newly Diagnosed Stage 1 Hypertensive Men With Erectile Dysfunction. |
Unknown status |
NCT01885988 |
Phase 4 |
Nebivolol;Sugar Pill |
3 |
Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate i.m. 1000 mg. A Prospective, Multi-Center Clinical Study Phase IV. |
Unknown status |
NCT00555087 |
Phase 4 |
Testosterone Undecanoate and/or PDE-5 |
4 |
a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency) |
Unknown status |
NCT03290313 |
Phase 4 |
shu gan yi yang capsule;shu gan yi yang capsule simulation agent |
5 |
Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury |
Unknown status |
NCT00725790 |
Phase 4 |
Vardenafil;Placebo |
6 |
Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction: Non- Inferiority, Randomized, Crossover, Open Clinical Trial |
Unknown status |
NCT03169582 |
Phase 4 |
Avanafil;Sildenafil |
7 |
A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy |
Unknown status |
NCT03142542 |
Phase 4 |
ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet |
8 |
Post-Prostatectomy Erectile Dysfunction: Effect of Hyperbaric Oxygen Therapy |
Unknown status |
NCT00906269 |
Phase 4 |
Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T |
9 |
Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis |
Unknown status |
NCT02344823 |
Phase 4 |
Vardenafil;Placebo intake once daily |
10 |
An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction. |
Unknown status |
NCT02225548 |
Phase 4 |
Selegiline;Tadalafil |
11 |
The Effect of Treatment for ED on Quality of Life and Satisfaction in a Group of Patients Without Prior Complaints of Sexual Dysfunction |
Unknown status |
NCT00313898 |
Phase 4 |
sildenafil (viagra) |
12 |
A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment |
Unknown status |
NCT01364701 |
Phase 4 |
Sildenafil 100 mg;Tadalafil 20 mg;Combination half of maximal dose for sildenafil & tadalafil |
13 |
A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment |
Unknown status |
NCT00498680 |
Phase 4 |
Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil |
14 |
Assessment of Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction |
Completed |
NCT05446493 |
Phase 4 |
Tadalafil 5mg |
15 |
A Randomized, Double Blind, Placebo Controlled, Flexible Dose, Multicentre Study of Levitra in a Broad Population of Men With Erectile Dysfunction and Previously Untreated With PDE5 Inhibitors. |
Completed |
NCT00668096 |
Phase 4 |
Levitra (Vardenafil, BAY38-9456);Placebo |
16 |
A Randomised, Double-blind, Double-dummy, Parallel-group, Active-controlled Study Evaluating the Efficacy of Vardenafil Versus Tadalafil When Intercourse is Attempted Within 45 Minutes of Administration in Subjects With Erectile Dysfunction |
Completed |
NCT00663130 |
Phase 4 |
Levitra (Vardenafil, BAY38-9456);Tadalafil |
17 |
An Open-label, Multi-center, Factorial Design, Cluster-randomized Clinical Study of Vardenafil in Canadian Males With Erectile Dysfunction: Impact of Education of the Primary Care Physician and Patient on Patient Outcomes. |
Completed |
NCT00664833 |
Phase 4 |
|
18 |
An International, Multicentre, Randomized, Parallel Group, Double Blind, Placebo Controlled, Flexible Dose Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfunction Treated With Sildenafil Citrate |
Completed |
NCT00648596 |
Phase 4 |
sildenafil;placebo |
19 |
A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Viagra® (Sildenafil Citrate) on the PRN Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes |
Completed |
NCT00645268 |
Phase 4 |
sildenafil;placebo |
20 |
A Placebo-Controlled, Randomized, Two-Way Cross-Over, Double-Blind, Flexible Dose, Multicenter Study to Evaluate the Efficacy and Safety of Viagra in Male Patients With Traumatic Spinal Cord Injury and Erectile Dysfunction |
Completed |
NCT00654082 |
Phase 4 |
sildenafil;placebo |
21 |
Evaluation of Systemic and Penile Microvascular Endothelial Function and Arterial Pressure After Chronic Administration of Sildenafil in Hypertensive Men With Erectile Dysfunction |
Completed |
NCT02620995 |
Phase 4 |
sildenafil citrate |
22 |
Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction (ED) Patients Previously Treated With Other Oral ED Therapy |
Completed |
NCT00422578 |
Phase 4 |
tadalafil |
23 |
Phase IV Study of The Therapy of Long-acting Testosterone Undecanoate,1000mg in 4 ml Oily Solution for i.m.Injection(Nebido) as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction |
Completed |
NCT00421460 |
Phase 4 |
Testosterone Undecanoate,1000mg |
24 |
A Randomized, Double Blind, Parallel Group Study of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction and Their Female Partners Sexual Quality of Life. PARTNER II |
Completed |
NCT00377793 |
Phase 4 |
Levitra (Vardenafil, BAY38-9456);Placebo |
25 |
A Randomized, Double Blind, Placebo-controlled, Parallel Group, Multi-center Study to Investigate the Responsiveness of the Erectile Quality Scale (EQS) to Vardenafil HCl Flexible Dose Versus Placebo in Males With Erectile Dysfunction. |
Completed |
NCT00665340 |
Phase 4 |
Placebo;Levitra (Vardenafil, BAY38-9456) |
26 |
A Rand, db, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Plac in Men With Diabetes Mellitus Type 1 and Erectile Dysfunction |
Completed |
NCT00660998 |
Phase 4 |
Levitra (Vardenafil, BAY38-9456);Placebo |
27 |
A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men With Erectile Dysfunction |
Completed |
NCT01698684 |
Phase 4 |
Placebo;Avanafil 100 mg;Avanafil 200 mg |
28 |
Multi-centre, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Assess the Efficacy and Tolerability of Vardenafil and Its Influence on Self-esteem and Self Confidence in Subjects With Erectile Dysfunction. |
Completed |
NCT00665054 |
Phase 4 |
Levitra (Vardenafil, BAY38-9456);Placebo |
29 |
A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Viagra (Sildenafil Citrate) And Cialis (Tadalafil) |
Completed |
NCT00644956 |
Phase 4 |
tadalafil;sildenafil |
30 |
Does Presence of Distress Due to Erectile Dysfunction Affect the Effect of Tadalafil on Sexual Life and Life Satisfaction? |
Completed |
NCT00547599 |
Phase 4 |
tadalafil |
31 |
Open-label, Multi-centre, Study to Investigate the Safety, Tolerability and Efficacy of Flexible Doses of Vardenafil Given on Demand in Males With Erectile Dysfunction |
Completed |
NCT00681772 |
Phase 4 |
Levitra (Vardenafil, BAY38-9456) |
32 |
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia. |
Completed |
NCT00663845 |
Phase 4 |
Levitra (Vardenafil, BAY38-9456);Placebo |
33 |
Open-Label, Multi-Centre, Study of Levitra 10 mg Once a Day in Males With Erectile Dysfunction Was Carried Out in Four Centres Namely Lagos, Port Harcourt, Enuge and Maiduguri at Their University Teaching Hospitals |
Completed |
NCT00662441 |
Phase 4 |
Levitra (Vardenafil, BAY38-9456) |
34 |
Double-blind, Placebo Controlled, Randomized Study of Vardenafil to Determine Efficacy on Erectile Dysfunction (ED) in Men With ED and Metabolic Syndrome (ED-METABOLIC) |
Completed |
NCT00738400 |
Phase 4 |
Vardenafil (Levitra, BAY38-9456);Placebo |
35 |
Randomised, Double Blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Study to Evaluate the Efficacy and Tolerability of Vardenafil (BAY 38-9456) in Treatment of Male Erectile Dysfunction in Asia |
Completed |
NCT00668135 |
Phase 4 |
Vardenafil (Levitra, BAY38-9456);Placebo |
36 |
Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Flexible, Titration Dose Administered on an As Needed Basis (PRN) to Evaluate the Efficacy and the Safety of Sildenafil for the Treatment of Erectile Dysfunction in Male Patients on Hemodialysis |
Completed |
NCT00654017 |
Phase 4 |
placebo;sildenafil |
37 |
A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) In The United States |
Completed |
NCT00644631 |
Phase 4 |
sildenafil;placebo |
38 |
Oral Administration of L-Arginine in Patients With Erectile Dysfunction |
Completed |
NCT00777075 |
Phase 4 |
L-arginine;Placebo |
39 |
Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference |
Completed |
NCT00547352 |
Phase 4 |
tadalafil;sildenafil |
40 |
A Multicenter Open-Label Study to Determine Treatment Preference of Tadalafil (IC351, LY450190) or Sildenafil Citrate in the Oral Treatment of Erectile Dysfunction |
Completed |
NCT00547092 |
Phase 4 |
tadalafil;sildenafil |
41 |
Androgen Modulation of Response to Selective Phosphodiesterase Inhibitors in Erectile Dysfunction |
Completed |
NCT00512707 |
Phase 4 |
Sildenafil citrate (open label);Testosterone gel |
42 |
A Multicenter, Open Label, High Dose (100mg) Rapid Titration Study, To Evaluate The Efficacy And Satisfaction Of Patrex® (Sildenafil Citrate) In Men With Erectile Dysfunction In Mexico. |
Completed |
NCT00468650 |
Phase 4 |
sildenafil citrate |
43 |
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia |
Completed |
NCT00379756 |
Phase 4 |
LEVITRA (vardenafil);placebo |
44 |
Multicenter Randomized Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose - II |
Completed |
NCT00143260 |
Phase 4 |
Viagra (Sildenafil Citrate) 100 mg |
45 |
A Multicenter, Randomized, Parallel Group, Double-blind, Placebo-controlled Flexible Dose Study With and Open-label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States |
Completed |
NCT00143221 |
Phase 4 |
Viagra;Placebo |
46 |
Effectiveness Of An Educational Program To Improve Patients' Satisfaction Regarding Their Management Of Erectile Dysfunction With Sildenafil |
Completed |
NCT00159848 |
Phase 4 |
|
47 |
An Open-Label, Non-Comparative Study To Evaluate Treatment Responsiveness To The Quality Of Erection Questionnaire (QEQ) In Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) |
Completed |
NCT00151463 |
Phase 4 |
sildenafil citrate |
48 |
Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naïve to PDE5 Inhibitors |
Completed |
NCT01122264 |
Phase 4 |
Tadalafil;Sildenafil Citrate |
49 |
A Multicenter, Parallel Group Flexible Dose Study With A Double Blind, Randomized, Placebo Controlled Phase And An Open-Label Phase To Evaluate The Quality Of Erections In Men With Erectile Dysfunction Treated With Sildenafil Citrate |
Completed |
NCT00159900 |
Phase 4 |
Sildenafil Citrate |
50 |
A Multi-Center, Flexible Dose Study With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Evaluate The Impact Of Treatment With Sildenafil Citrate On The Symptoms Of Depression And Quality Of Life (Qol) Of Male Patients With Erectile Dysfunction (ED) |
Completed |
NCT00159809 |
Phase 4 |
Viagra (Sildenafil citrate) |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Ginseng Preparation
Methyltestosterone
METHYLTESTOSTERONE PWDR
Papaverine
|
Papaverine Hydrochloride
yohimbine
Yohimbine hydrochloride
|
|